President & CEO
Dr. Antony Loebel is President and CEO of Sunovion Pharmaceuticals Inc., a global
biopharmaceutical company with over 1,600 employees focused on the innovative application of
science and medicine to help people with serious medical conditions.
Sunovion's track record of discovery, development and commercialization of important psychiatric,
neurological and respiratory therapies has included Latuda® (lurasidone HCI), Brovana®
(arformoterol tartrate), Aptiom® (eslicarbazepine acetate) and Lonhala® Magnair® (glycopyrrolate)
Dr. Loebel joined the Company in 2007. His prior industry experience includes seven years in drug
development and medical affairs roles at Pfizer. He serves as an Executive Leadership Team member
of Sunovion and an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd., the parent company
of Sunovion. Dr. Loebel also serves on the Pharmaceutical Research and Manufacturers of America
(PhRMA) Board of Directors and previously served on the Massachusetts Biotechnology Council
(MassBio) Board of Directors.
During his tenure at Sunovion, Dr. Loebel has provided strategic direction and leadership of
Research & Development (R&D), including overseeing the Global Clinical Development organization.
In this role, he directed initiatives designed to improve global R&D operational efficiency and to
address unmet medical needs through innovation in drug development. Dr. Loebel’s scientific work
has led to the publication of numerous articles on the diagnosis and treatment of severe mental
Dr. Loebel is a board-certified psychiatrist, a Clinical Assistant Professor of Psychiatry at the New
York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a
member of the American College of Neuropsychopharmacology (ACNP). For his achievements in
advancing new treatments for CNS disorders, the International Society for CNS Drug Development
(ISCDD) presented Dr. Loebel with its Award for Leadership.
Selected by PharmaVOICE in 2019 and 2013 as one of the "100 Most Inspiring People" in the
pharmaceutical industry, Dr. Loebel is widely recognized by his peers as an innovative and
collaborative leader guided by his dedication to patients.
Dr. Loebel earned a M.D. from the University of Washington School of Medicine in Seattle. He
completed his residency in Psychiatry and a research fellowship in Clinical Neurosciences at Zucker
Hillside Hospital (Northwell Health) in Glen Oaks, New York. Dr. Loebel holds a Bachelor of Arts
degree with Majors in Zoology and English (with Distinction) from the University of Washington.